FDA Orange Book
Generic for Anaprox
Anaprox contains naproxen. Orange Book status for every listed strength, the approved generic makers, and the listed patents and exclusivities.
Source: FDA Orange Book data file dated 2026-10-09. Publisher page
Yes. The generic name for Anaprox is naproxen. 4 companies hold an active FDA approval (ANDA) for a generic version in the Orange Book. Therapeutic equivalence codes: AB.
Run it in Rivvi
Map Anaprox and your other top fills to their generics
Every strength in RxNorm, with brands that have no generic flagged.
Build the mapFree to start. Opens Rivvi, the AI workspace for healthcare teams.
Anaprox products in the Orange Book
| Form and route | Strength | Brand status | Brand TE | Active generics | Generic TE codes |
|---|---|---|---|---|---|
| tablet, oral | EQ 250MG BASE | Discontinued | None | 4 | AB |
NDA 018164, held by ATNAHS PHARMA US LTD. Active generics are ANDA products in the Orange Book prescription list with the same ingredient, dosage form, route and strength.
Approved generic naproxen
| Company | ANDA | TE code | Approved | Strengths |
|---|---|---|---|---|
| GLENMARK PHARMACEUTICALS LTD | 078314 | AB (A-rated, therapeutically equivalent) | April 27, 2007 | EQ 250MG BASE |
| DR REDDYS LABORATORIES LTD | 078486 | AB (A-rated, therapeutically equivalent) | July 26, 2007 | EQ 250MG BASE |
| AUROBINDO PHARMA LTD | 200629 | AB (A-rated, therapeutically equivalent) | October 31, 2011 | EQ 250MG BASE |
| SCIEGEN PHARMACEUTICALS INC | 212199 | AB (A-rated, therapeutically equivalent) | October 30, 2019 | EQ 250MG BASE |
Questions
Is there a generic for Anaprox?
Yes. The generic name for Anaprox is naproxen. 4 companies hold an active FDA approval (ANDA) for a generic version in the Orange Book. Therapeutic equivalence codes: AB.
What is the generic name for Anaprox?
The active ingredient in Anaprox is naproxen, per the FDA Orange Book.
What does a therapeutic equivalence code mean?
In the Orange Book, codes that start with A (such as AB) mean FDA considers the product therapeutically equivalent to the reference drug. Codes that start with B mean FDA does not, at this time, consider the product therapeutically equivalent.